Sionna Therapeutics shares are trading lower after the company reported topline data from the PreciSION CF Phase 2a proof-of-concept trial of SION-719 did not achieve key activity endpoint.

Benzinga Newsdesk www.benzinga.com Negative 97.1%

Neg 97.1% Neu 0% Pos 0%

Comments

No comments yet. Be the first!